menu
    • menu

    Find Carvedilol manufacturers, exporters & distributors on PharmaCompass

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    62

    API Suppliers

    API Suppliers

    24

    USDMF

    US DMFs Filed

    23

    CEP/COS

    CEP/COS Certifications

    5

    JDMF

    JDMFs Filed

    15

    EU WC

    EU WC

    40

    KDMF

    KDMF

    14

    NDC API

    NDC API

    0

    VMF

    NDC API

    37

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 293

    MARKET PLACE

    14

    API

    10

    FDF

    33INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    520

    FDF Dossiers

    FDF Dossiers

    72

    FDA Orange Book

    FDA (Orange Book)

    262

    Europe

    Europe

    36

    Canada

    Canada

    46

    Australia

    Australia

    30

    South Africa

    South Africa

    74

    Listed Dossiers

    Listed Dossiers

    0 DRUGS IN DEVELOPMENT

    FDF DossiersDRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    3

    EDQM

    4

    USP

    0

    JP

    8

    Others

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    10

    Health Canada Patents

    DIGITAL CONTENT

    1

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    17

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    177,808,465

    Annual Reports

    589

    Finished Drug Prices

    Listed Dossiers

    282 RELATED EXCIPIENT COMPANIES

    490EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 72956-09-3, Coreg, Dilatrend, Eucardic, Kredex, Carvedilolum [latin]
    Molecular Formula
    C24H26N2O4
    Molecular Weight
    406.5  g/mol
    InChI Key
    OGHNVEJMJSYVRP-UHFFFAOYSA-N
    FDA UNII
    0K47UL67F2
    Carvedilol
    A carbazole and propanol derivative that acts as a non-cardioselective beta blocker and vasodilator. It has blocking activity for ALPHA 1 ADRENERGIC RECEPTORS and, at higher doses, may function as a blocker of CALCIUM CHANNELS; it also has antioxidant properties. Carvedilol is used in the treatment of HYPERTENSION; ANGINA PECTORIS; and HEART FAILURE. It can also reduce the risk of death following MYOCARDIAL INFARCTION.
    Carvedilol is an alpha-Adrenergic Blocker and beta-Adrenergic Blocker. The mechanism of action of carvedilol is as an Adrenergic alpha-Antagonist and Adrenergic beta1-Antagonist and Adrenergic beta2-Antagonist.
    1 2D Structure

    Carvedilol

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol
    2.1.2 InChI
    InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3
    2.1.3 InChI Key
    OGHNVEJMJSYVRP-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O
    2.2 Other Identifiers
    2.2.1 UNII
    0K47UL67F2
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 14c-labeled Carvedilol

    2. Bm 14190

    3. Bm-14190

    4. Bm14190

    5. Carvedilol Hydrochloride

    6. Carvedilol, (+)

    7. Carvedilol, (+)-isomer

    8. Carvedilol, (+-)-isomer

    9. Carvedilol, (-)

    10. Carvedilol, (-)-isomer

    11. Carvedilol, (r)-isomer

    12. Carvedilol, (s)-isomer

    13. Carvedilol, 14c Labeled

    14. Carvedilol, 14c-labeled

    15. Coreg

    16. Coropres

    17. Dilatrend

    18. Eucardic

    19. Kredex

    20. Querto

    2.3.2 Depositor-Supplied Synonyms

    1. 72956-09-3

    2. Coreg

    3. Dilatrend

    4. Eucardic

    5. Kredex

    6. Carvedilolum [latin]

    7. Carvedilolum

    8. Querto

    9. Bm 14190

    10. 1-(9h-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol

    11. Bm-14190

    12. Dimitone

    13. Artist

    14. Skf 105517

    15. 1-(9h-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol

    16. 1-((9h-carbazol-4-yl)oxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol

    17. Coronis

    18. Korvasan

    19. Talliton

    20. Dq 2466

    21. Dq-2466

    22. C07ag02

    23. (+-)-1-(carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol

    24. Chembl723

    25. Nsc-758694

    26. Sk&f-105517

    27. Bm 14.190

    28. Bm-14-190

    29. Bm-14.190

    30. Chebi:3441

    31. 0k47ul67f2

    32. [3-(9h-carbazol-4-yloxy)-2-hydroxypropyl][2-(2-methoxyphenoxy)ethyl]amine

    33. 1-(9h-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol

    34. Skf-105517

    35. (r)-bm 14190

    36. (s)-bm 14190

    37. Coropress

    38. Dibloc

    39. R-(+)-carvedilol

    40. S-(-)-carvedilol

    41. 1-(9h-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol

    42. Smr000449280

    43. Artist (tn)

    44. Coreg (tn)

    45. Hsdb 7044

    46. Sr-01000759289

    47. Unii-0k47ul67f2

    48. Mfcd00869663

    49. 1-(9h-carbazol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)propan-2-ol

    50. Carvedilol D5

    51. Eg-p042

    52. Mfcd00864692

    53. Carvedilol - Bio-x

    54. Bm14190

    55. Carvedilol [usan:usp:inn:ban:jan]

    56. Spectrum_001665

    57. Carvedilol [mi]

    58. Carvedilol [inn]

    59. Carvedilol [jan]

    60. Spectrum2_001673

    61. Spectrum3_001182

    62. Spectrum4_000636

    63. Spectrum5_001436

    64. Carvedilol [hsdb]

    65. Carvedilol [usan]

    66. Carvedilol [vandf]

    67. Carvedilol [mart.]

    68. Carvedilol [usp-rs]

    69. Carvedilol [who-dd]

    70. Schembl22293

    71. Gtpl551

    72. Kbiogr_001252

    73. Kbioss_002145

    74. Mls000758299

    75. Mls000759508

    76. Mls001424092

    77. Mls006011886

    78. Spbio_001885

    79. Carvedilol (jp17/usp/inn)

    80. Carvedilol [orange Book]

    81. Dtxsid8022747

    82. Schembl10082334

    83. Schembl13287211

    84. Bdbm25759

    85. Kbio2_002145

    86. Kbio2_004713

    87. Kbio2_007281

    88. Kbio3_002323

    89. Carvedilol [ep Monograph]

    90. (r)-1-[(4-carbazolyl)oxy]-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol

    91. Carvedilol [usp Monograph]

    92. Hms2051n03

    93. Hms2089b09

    94. Hms2093e12

    95. Hms3261e15

    96. Hms3269n11

    97. Hms3393n03

    98. Hms3413b14

    99. Hms3655o14

    100. Hms3677b14

    101. Hms3715d15

    102. Hms3750i15

    103. Hms3884e12

    104. Pharmakon1600-01504257

    105. Carvedilol 1.0 Mg/ml In Methanol

    106. ((c)i)-carvedilol-d4(ethyl-d4)

    107. Amy40801

    108. Bcp23386

    109. Ex-a5746

    110. Hy-b0006

    111. Tox21_500347

    112. Bbl029064

    113. Mfcd00869664

    114. Nsc758694

    115. S1831

    116. Stk621453

    117. Akos005554967

    118. Carvedilol, >=98% (hplc), Solid

    119. Ac-1641

    120. Bcp9000493

    121. Ccg-100917

    122. Ccg-207952

    123. Cs-1194

    124. Db01136

    125. Ks-1037

    126. Lp00347

    127. Nc00167

    128. Nsc 758694

    129. Sb17441

    130. Sdccgsbi-0206771.p002

    131. 2-propanol, 1-(9h-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-, (+-)-

    132. Ncgc00167832-01

    133. Ncgc00167832-02

    134. Ncgc00167832-03

    135. Ncgc00167832-04

    136. Ncgc00167832-19

    137. Ncgc00261032-01

    138. Bc164291

    139. Sy129821

    140. Sy283162

    141. Bcp0726000253

    142. Sbi-0206771.p001

    143. Db-055704

    144. Db-057556

    145. Db-057557

    146. Ft-0603055

    147. Ft-0603057

    148. Ft-0652640

    149. Ft-0664397

    150. Sw197547-3

    151. C06875

    152. D00255

    153. F19969

    154. Ab00639903-07

    155. Ab00639903-09

    156. Ab00639903_10

    157. Ab00639903_11

    158. Ab00639903_12

    159. 956c093

    160. L001243

    161. Q412534

    162. Q-200801

    163. Sr-01000759289-5

    164. Sr-01000759289-6

    165. Sr-01000759289-9

    166. Brd-a10977446-001-04-8

    167. Brd-a10977446-001-05-5

    168. Brd-a10977446-045-01-1

    169. Z2786051695

    170. Carvedilol, European Pharmacopoeia (ep) Reference Standard

    171. Ethyl 2-(9-(pyridin-4-ylmethyl)-9h-fluoren-9-yl)acetate

    172. Carvedilol, United States Pharmacopeia (usp) Reference Standard

    173. 1-(9h-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol

    174. Carvedilol, Pharmaceutical Secondary Standard; Certified Reference Material

    175. (+/-)-1-carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol

    176. 1-(carbazol-4-yloxy)-3-((2-(o-methoxy-phenoxy)ethyl)amino)-2-propanol

    177. Carvedilol For System Suitability, European Pharmacopoeia (ep) Reference Standard

    178. 107741-96-8

    179. 2-propanol, 1-(9h-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-, (+/-)-

    2.4 Create Date
    2005-03-25
    3 Chemical and Physical Properties
    Molecular Weight 406.5 g/mol
    Molecular Formula C24H26N2O4
    XLogP34.2
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count5
    Rotatable Bond Count10
    Exact Mass406.18925731 g/mol
    Monoisotopic Mass406.18925731 g/mol
    Topological Polar Surface Area75.7 Ų
    Heavy Atom Count30
    Formal Charge0
    Complexity508
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count1
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 6  
    Drug NameCarvedilol
    PubMed HealthCarvedilol (By mouth)
    Drug ClassesAntianginal, Antihypertensive, Cardiovascular Agent
    Drug LabelCarvedilol is a nonselective -adrenergic blocking agent with 1-blocking activity. It is ()-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. Carvedilol is a racemic mixture with the following structure:Carvedilol tablets, US...
    Active IngredientCarvedilol
    Dosage FormTablet
    RouteOral
    Strength6.25mg; 25mg; 3.125mg; 12.5mg
    Market StatusPrescription
    CompanyRanbaxy; Glenmark Generics; Teva; Apotex; Aurobindo Pharma; Sun Pharm Inds; Beximco Usa; Pliva Hrvatska Doo; Taro; Lupin; Zydus Pharms Usa; Dr Reddys Labs; Sandoz; Cipla; Mylan; Hikma

    2 of 6  
    Drug NameCoreg
    PubMed HealthCarvedilol (By mouth)
    Drug ClassesAntianginal, Antihypertensive, Cardiovascular Agent
    Drug LabelCarvedilol is a nonselective -adrenergic blocking agent with 1-blocking activity. It is ()-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. Carvedilol is a racemic mixture with the following structure:COREG is a white, oval...
    Active IngredientCarvedilol
    Dosage FormTablet
    RouteOral
    Strength6.25mg; 25mg; 3.125mg; 12.5mg
    Market StatusPrescription
    CompanySmithkline Beecham

    3 of 6  
    Drug NameCoreg cr
    PubMed HealthCarvedilol (By mouth)
    Drug ClassesAntianginal, Antihypertensive, Cardiovascular Agent
    Active IngredientCarvedilol phosphate
    Dosage FormCapsule, extended release
    RouteOral
    Strength10mg; 80mg; 40mg; 20mg
    Market StatusPrescription
    CompanySb Pharmco

    4 of 6  
    Drug NameCarvedilol
    PubMed HealthCarvedilol (By mouth)
    Drug ClassesAntianginal, Antihypertensive, Cardiovascular Agent
    Drug LabelCarvedilol is a nonselective -adrenergic blocking agent with 1-blocking activity. It is ()-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. Carvedilol is a racemic mixture with the following structure:Carvedilol tablets, US...
    Active IngredientCarvedilol
    Dosage FormTablet
    RouteOral
    Strength6.25mg; 25mg; 3.125mg; 12.5mg
    Market StatusPrescription
    CompanyRanbaxy; Glenmark Generics; Teva; Apotex; Aurobindo Pharma; Sun Pharm Inds; Beximco Usa; Pliva Hrvatska Doo; Taro; Lupin; Zydus Pharms Usa; Dr Reddys Labs; Sandoz; Cipla; Mylan; Hikma

    5 of 6  
    Drug NameCoreg
    PubMed HealthCarvedilol (By mouth)
    Drug ClassesAntianginal, Antihypertensive, Cardiovascular Agent
    Drug LabelCarvedilol is a nonselective -adrenergic blocking agent with 1-blocking activity. It is ()-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. Carvedilol is a racemic mixture with the following structure:COREG is a white, oval...
    Active IngredientCarvedilol
    Dosage FormTablet
    RouteOral
    Strength6.25mg; 25mg; 3.125mg; 12.5mg
    Market StatusPrescription
    CompanySmithkline Beecham

    6 of 6  
    Drug NameCoreg cr
    PubMed HealthCarvedilol (By mouth)
    Drug ClassesAntianginal, Antihypertensive, Cardiovascular Agent
    Active IngredientCarvedilol phosphate
    Dosage FormCapsule, extended release
    RouteOral
    Strength10mg; 80mg; 40mg; 20mg
    Market StatusPrescription
    CompanySb Pharmco

    4.2 Therapeutic Uses

    Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Vasodilator Agents

    National Library of Medicine's Medical Subject Headings online file (MeSH, 2009)

    Carvedilol is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization. /Included in US product label/

    US Natl Inst Health; DailyMed. Current Medication Information for CARVEDILOL (carvedilol) tablet (May 2011). Available from, as of September 19, 2011: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b802a9c-332f-4ea8-bb34-75c677264654

    Carvedilol is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of greater than 40 percent (with or without symptomatic heart failure). /Included in US product label/

    US Natl Inst Health; DailyMed. Current Medication Information for CARVEDILOL (carvedilol) tablet (May 2011). Available from, as of September 19, 2011: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b802a9c-332f-4ea8-bb34-75c677264654

    Carvedilol is indicated for the management of essential hypertension. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. /Included in US product label/

    US Natl Inst Health; DailyMed. Current Medication Information for CARVEDILOL (carvedilol) tablet (May 2011). Available from, as of September 19, 2011: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b802a9c-332f-4ea8-bb34-75c677264654

    For more Therapeutic Uses (Complete) data for CARVEDILOL (10 total), please visit the HSDB record page.

    4.3 Drug Warning

    Carvedilol is contraindicated in the following conditions: Bronchial asthma or related bronchospastic conditions. Deaths from status asthmaticus have been reported following single doses of carvedilol; second- or third-degree AV block; sick sinus syndrome; severe bradycardia (unless a permanent pacemaker is in place); Patients with cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic therapy. Such patients should first be weaned from intravenous therapy before initiating carvedilol; patients with severe hepatic impairment; patients with a history of a serious hypersensitivity reaction (eg, Stevens-Johnson syndrome, anaphylactic reaction, angioedema) to any component of this medication or other medications containing carvedilol.

    US Natl Inst Health; DailyMed. Current Medication Information for CARVEDILOL (carvedilol) tablet (May 2011). Available from, as of September 19, 2011: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b802a9c-332f-4ea8-bb34-75c677264654

    Patients with coronary artery disease, who are being treated with carvedilol, should be advised against abrupt discontinuation of therapy. Severe exacerbation of angina and the occurrence of myocardial infarction and ventricular arrhythmias have been reported in angina patients following the abrupt discontinuation of therapy with beta-blockers. The last 2 complications may occur with or without preceding exacerbation of the angina pectoris. As with other beta-blockers, when discontinuation of carvedilol is planned, the patients should be carefully observed and advised to limit physical activity to a minimum. Carvedilol should be discontinued over 1 to 2 weeks whenever possible. If the angina worsens or acute coronary insufficiency develops, it is recommended that carvedilol be promptly reinstituted, at least temporarily. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue therapy with carvedilol abruptly even in patients treated only for hypertension or heart failure.

    US Natl Inst Health; DailyMed. Current Medication Information for CARVEDILOL (carvedilol) tablet (May 2011). Available from, as of September 19, 2011: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b802a9c-332f-4ea8-bb34-75c677264654

    Worsening heart failure or fluid retention may occur during up-titration of carvedilol. If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes. Occasionally it is necessary to lower the carvedilol dose or temporarily discontinue it. Such episodes do not preclude subsequent successful titration of, or a favorable response to, carvedilol. In a placebo-controlled trial of patients with severe heart failure, worsening heart failure during the first 3 months was reported to a similar degree with carvedilol and with placebo. When treatment was maintai